Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Temuterkib with or without Hydroxychloroquine in Metastatic Pancreatic Cancer
NCT04386057Phase 2Completed
- Start
- May 2020
- Primary completion
- Aug 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of temuterkib in pancreatic cancer (PC) (4 arms). Primary endpoints: Disease Control Rate at 28 months and Dose Limiting Toxicity at 28 days. Started May 2020; status: completed.
02
Drugs
temuterkib
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT04386057.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04386057.